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Abstract
Reverse transfection microarrays were described recently as a high throughput
method for studying gene function. We have investigated the use of this technology for
determining the subcellular localization of proteins. Genes encoding 16 proteins with
a variety of functions were placed in Gateway expression constructs with 3′ or 5′ green
fluorescent protein (GFP) tags. These were then packaged in transfection reagent and
spotted robotically onto a glass slide to form a reverse transfection array. HEK293T
cells were grown over the surface of the array until confluent and GFP fluorescence
visualized by confocal microscopy. All C-terminal fusion proteins localized to cellular
compartments in accordance with previous studies and/or bioinformatic predictions.
However, less than half of the N-terminal fusion proteins localized correctly. Of those
that were not in concordance with the C-terminal tagged proteins, half did not exhibit
expression and the remainder had differing subcellular localizations to the C-terminal
fusion protein. This data indicates that N-terminal tagging with GFP adversely affects
the protein localization in reverse transfection assays, whereas tagging with GFP at
the C-terminal is generally better in preserving the localization of the native protein.
We discuss these results in the context of developing high-throughput subcellular
localization assays based on the reverse transfection array technology. Copyright 
2004 John Wiley & Sons, Ltd.
Keywords: reverse transfection; subcellular localization; signal sequence; C- and
N-terminal tag; cell-based array
Introduction
Reverse transfection (Ziauddin, 2001) is a power-
ful new technology with the potential to provide
a high throughput screen of gene function, iden-
tification of novel drug targets and determination
of the subcellular localization of proteins (Wu,
2002; Bailey, 2002). Reverse transfection tech-
nology entails inserting full-length open reading
frames (ORFs) of genes of interest (GOI) into an
expression vector. These vectors are then packaged
into a transfection reagent and printed onto a glass
slide to form a microarray. Cells are grown over
the top of the array until confluent and patches
of transfected cells overexpressing the genes are
formed (Figure 1). Arrays can then be examined
for alterations in cellular function as manifested
in changes to the biochemistry or morphology of
cells. If the expression vector contains a ‘tag’, the
subcellular localization of the transgene can also
be analysed. Using this approach, large numbers of
assays can be performed in a single study.
In order to tag proteins for determination of
their localization, two basic approaches are utilized
for detection; epitope tagging, or tagging of the
GOI with a protein that is fluorescent or possesses
enzymatic activity. Epitope tags are small peptides
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(3–14 amino acids), e.g. His6 and c-myc, which
can be detected by immunohistochemistry. Due
to their small size, they are less likely to disrupt
the normal function or localization of the protein.
However, immunohistochemical detection is time-
consuming, and processing can be disruptive to the
layer of cells growing over the array and can only
be performed on fixed cells. Alternatively, protein
tags such as luciferase, β-galactosidase (β-gal) and
green fluorescent protein (GFP) can be detected
through their innate activity. GFP has the advantage
that it is stable for months, can be visualized easily
via standard confocal or fluorescent microscopy
(Lippincot-Schwartz, 2003), is readily available in
expression vectors such as the Invitrogen Gateway
cloning system and can be detected in living cells.
We wished to investigate the use of GFP to study
the subcellular localization of proteins following
reverse transfection. In particular, we sought to study
the effect of positioning GFP at either the N- or C-
terminal on the subcellular localization of the fusion
protein — if this is disrupted relative to the native
protein, so presumably will be the normal functional
activity of the protein. In order to establish a work-
ing protocol for reverse transfection and explore its
potential as a high-throughput screen of subcellu-
lar localization, we selected 16 genes from three
functional classes; kinase, transcription factor and
surface receptor. In addition, the genes were selected
because they were of a range of sizes and were
known to localize to differing subcellular compart-
ments (recorded by Swiss-Prot). The Mammalian
Gene Collection (MGC; Strausberg, 2002) was cho-
sen as a library from which to obtain the genes as
it contains a large number of full-length, sequence-
verified open ORFs. The genes were amplified and
placed into Gateway destination N- and C-terminal
GFP fusion vectors. Using the reverse transfec-
tion strategy, these constructs were transfected into
HEK293T (human embryonic kidney) and the sub-
cellular localization of the transgene recorded. These
observations were correlated with the documented
and/or predicted localizations for these proteins,
allowing the effect of tagging to be examined.
Materials and methods
Amplification of gene of interest (GOI) open
reading frames (ORF)
Sequence verified open reading frames (ORFs) in
the vector pCMV-SPORT6 (Invitrogen, Paisley,
UK), were obtained from MRC gene-services
(HGMP-RC, UK), which are part of the IRAT
set from the MGC collection. Replicate working
plates were prepared in LB media containing 8%
glycerol (Sigma, Dorset, UK) and 50 µg/ml ampi-
cillin (Sigma), grown at 37 ◦C overnight and stored
at −70 ◦C. 5′ primers were designed with CACC
(to facilitate insertion of the GOI into the Gate-
way entry vector pENTR/D-TOPO) plus a further
18 bp from the first bp of the start codon. 3′
primers were designed with 18 bp before the first
bp of the stop codon (in order that transcription
can continue through the gene to the stop codon
of the C-terminal GFP). The melting temperature
(Tm) of the primers was calculated using the for-
mula: [6.93 + 0.41(%G + C)] — (650/l) (Chester,
1993). 55–60 ◦C was the ideal for each primer
pair; if necessary, bases were added or removed to
compensate and the primer pairs were checked for
non-complementarity using a Jemboss programme,
Water; http://www.hgmp.mrc.ac.uk/Software/
EMBOSS/Jemboss. For the sequence of all pri-
mers used in this study, see Table 1. A 20 µl
aliquot of the IRAT clone culture from the repli-
cate plates was added to 180 µl water to lyse the
Escherichia coli cells and 3 µl of each clone dilu-
tion was added to a PCR reaction mix containing:
2.5 µl 10× amplification buffer (provided with Pfx
polymerase), 0.75 µl 10 mM dNTP, 0.5 µl 50 mM
MgSO4, 100 ng 5′ primer, 100 ng 3′ primer mix,
0.3 µl 2.5 U/µl Pfx polymerase (Invitrogen, Pais-
ley, UK) and made up to 25 µl with H2O. A control
reaction was set up as above with primers to the
pCMV–SPORT-6 vector either side of the GOI. If
reactions failed, they were repeated with an anneal-
ing temperature of 55 ◦C. Amplified ORFs were
purified using the Qiaquick PCR purification kit
(Qiagen); the correct sizes were confirmed using
an Agilent Bioanalyzer 2100 (Agilent, West Loth-
ian, UK).
Transfer of amplified ORFs into
pENTR/D-TOPO clones
pENTR/D-TOPO is an entry vector for the Gate-
way cloning system. It is supplied linearized with
a GTGG overhang end and a blunt end to allow
the GOI ORFs with a CACC overhang to insert
in one direction only. The 16 GOIs and a control
were inserted into pENTR/D-TOPO and then trans-
formed in One Shot TOP10 E. coli cells, accord-
ing to the manufacturer’s instructions (Invitrogen);
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Table 1. Forward and reverse primers for amplification of ORFs from IRAT clones in pCMV-SPORT6 vectors
Gene Primers Sequence Gene Primers Sequence
ATF4 Forward 5′-caccatgaccgaaatgagcttc-3′ NFIL3 Forward 5′-caccatgcagctgagaaaaatg-3′
Reverse 5′-ggggacccttttcttccc-3′ Reverse 5′-cccagagtctgaagcaga-3′
CALM2 Forward 5′-caccatggctgaccaactgact-3′ PPARG Forward 5′-caccatgaccatggttgacaca-3′
Reverse 5′-ctttgctgtcatcatttgtacaaactc-3′ Reverse 5′-gtacaagtccttgtagatctc-3′
CDK7 Forward 5′-caccatggctctggacgtgaag-3′ PTPN11 Forward 5′-caccatgacatcgcggagatgg-3′
Reverse 5′-aaaaattagtttcttgggcaatcc-3′ Reverse 5′-cctgcagtgcaccacgac-3′
CDK9 Forward 5′-caccatggcgaagcagtacgac-3′ SIP2-28 Forward 5′-caccatggggggctcgggcagt-3′
Reverse 5′-gaagacgcgctcaaactcc-3′ Reverse 5′-caggacaatcttaaaggagctg-3′
CDKN1B Forward 5′-caccatgtcaaacgtgcgagtg-3′ STK15 Forward 5′-caccatggaccgatctaaagaa-3′
Reverse 5′-cgtttgacgtcttctgaggc-3′ Reverse 5′-agactgtttgctagctgattc-3′
CXADR Forward 5′-caccatggcgctcctgctgtgc-3′ TGIF Forward 5′-caccatgaaaggcaagaaaggt-3′
Reverse 5′-tactatagacccatccttgct-3′ Reverse 5′-agctgtaagttttgcctgaag-3′
IL17BR Forward 5′-caccatgtcgctcgtgctgcta-3′ TNFRSF10B Forward 5′-caccatggaacaacggggacag-3′
Reverse 5′-caaggagcagcagccatc-3′ Reverse 5′-ggacatggcagagtctgca-3′
MARKL1 Forward 5′-caccatggcagctctgcgccag-3′ SP6 (pCMV-SPORT6) Reverse 5′-atttaggtgacactatag-3′
Reverse 5′-gagctcgaggtcgttgga-3′ M13 (pENTR/D-TOPO) Forward 5′-gtaaaacgacggcc-3′
NFIB Forward 5′-caccatgatgtattctcccatc-3′ T7 (CMV-SPORT6/ Forward 5′-taatacgactcactataggg-3′
Reverse 5′-gcccaggtaccaggactg-3’ pcDNA-DEST47+53)
Primers were designed with a CACC overhang at the 5′ end to facilitate gene insertion into the Gateway pENTR/D-TOPO entry vector and
also to remove the stop site from the GOI for subsequent fusion with the C-terminal GFP.
they were then spread onto 50 µg/ml kanamycin
(Sigma) 2XTY agar plates and incubated at 37 ◦C
overnight. Five colonies were picked for each gene
and cultured overnight in 5 ml LB medium con-
taining 100 µg/ml kanamycin. 15% glycerol stocks
were prepared with 1 ml of the overnight culture
and the remainder was purified with the Concert
plasmid miniprep system, according to the manu-
facturer’s instructions (Invitrogen).
Ligation, propagation and linearization of
destination vectors
pcDNA-Dest53 and 47 are destination vectors for
Invitrogen’s Gateway cloning system and form
fusion genes with GFP at the 3′ or 5′ end, respec-
tively. They are supplied linearized, and so were
ligated prior to propagation. The ligation reaction
contained 150 ng pc-DNA-Dest47 or 53, 1 U T4
DNA ligase (Roche, Basel, Switzerland), 4 µl 10×
ligase buffer and was made up to 40 µl with H2O.
The reaction was incubated at room temperature
for 3 h. The DNA from the ligation reactions was
diluted five-fold in 10 mM Tris–HCl (pH 7.5) and
1 mM EDTA, 1 µl (10 ng DNA) of the dilution was
added to DB3.1-competent E. coli cells (Invitro-
gen), which are resistant to the ccdB gene con-
tained in pcDNA-Dest47 and 53 before recombi-
nation. 150 µl was plated onto a 100 µg/ml ampi-
cillin LB plate and incubated overnight at 37 ◦C.
10 colonies were picked and grown up overnight in
5 ml LB medium containing 100 µg/ml ampicillin
(Sigma). For the most efficient recombination with
the entry clone, the destination vector needs to be
linear, therefore a restriction digest was prepared
with 3 µl 10 × buffer, 0.3 µl 10 mg/ml BSA, 1 µg
pcDNA-Dest47 or 53 and made up to 30 µl with
H2O. 0.75 µl EcoR1 (Promega) was added and the
digest incubated at 37 ◦C for 1 h.
Figure 1. Reverse transfection strategy. (1,2) The genes of interest (GOI) were amplified from MGC clones in the
pCMV-SPORT6 vector. Primers were designed with a CACC overhang at the 5′ end to facilitate gene insertion into
the Gateway pENTR/D-TOPO entry vector and also to remove the stop site from the GOI for subsequent fusion
with the C-terminal GFP. (3) Once in the entry vector the gene was recombined into Gateway destination vectors
pcDNA–Dest47 (C-terminal fusion GFP) and pcDNA–Dest53 (N-terminal fusion GFP). (4,5) The vector was packaged
in Effectene transfection reagent and spotted onto a glass slide in a 10 × 10 grid (purple squares indicate C-terminal GFP
fusions and orange squares N-terminal fusions). (6) HEK293T cells were grown over the array to a confluent monolayer.
(7) Patches of transfected cells and the subcellular localizations of the expressed GFP fusion proteins were visualized by
confocal microscopy
Copyright  2004 John Wiley & Sons, Ltd. Comp Funct Genom 2004; 5: 342–353.
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Recombination of pENTR/D-TOPO and
pcDNA-Dest47 and 53 (LR reaction)
The LR reaction was prepared with 4 µl LR reac-
tion buffer, 300 ng pENTR/D-TOPO containing
GOI, 300 ng pcDNA-dest47 or 53, 4 µl LR clonase
enzyme mix and made up to 20 µl with TE buffer.
It was incubated at 25 ◦C for 60 min, 2 µl pro-
teinase K (Invitrogen) was added to stop the reac-
tion and then incubated at 37 ◦C for 10 min. The
reactions were transformed in DH5α cells accord-
ing to the manufacturer’s instructions (Invitrogen).
10 µl and 100 µl were plated onto 100 µg/ml ampi-
cillin plates and incubated overnight at 37 ◦C.
Three colonies from each gene were picked
and incubated overnight at 37 ◦C in 5 ml LB
medium containing 100 µg/ml ampicillin. Glycerol
stocks were made and the plasmid purified as for
pENTR/D-TOPO vectors.
Confirmatory PCR
pENTR/D-TOPO
A PCR reaction was set up for each GOI, pos-
itive and negative (no DNA) controls, contain-
ing 2 µl 10 × buffer, 0.5 µl 10 mM dNTP, 1 µg
pENTR/D-TOPO vector containing GOI, 0.2 µl
Taq polymerase, 100 ng 5′ vector specific M13
primer (Table 1) 100 ng 3′ gene specific primer
(Table 1), and made up to 20 µl with H2O. PCR
cycling was performed as follows: 94 ◦C 15 min;
then (94 ◦C 1 min, 55–60 ◦C 2 min, 72 ◦C 7 min)
×30 cycles; finally 72 ◦C 10 min. Annealing tem-
peratures were dependent upon empirical determi-
nation of the optimum PCR primer conditions.
pcDNA-Dest 47 and 53
Confirmatory PCR was carried out as for pENTR/
D-TOPO with the 5′ vector primer T7 (Table 1) and
the gene-specific 3′ primer (Table 1). The correct
sizes of the amplified GOI ORF were confirmed
using an Agilent Bioanalyzer 2100.
Reverse transfection
Destination vectors containing the GOI were pre-
packaged in the transfection reagent Effectene
(Qiagen) prior to printing. 1 µg pcDNA-Dest47
or 53 containing the GOI was added to 15 µl
DNA condensation buffer. 1.5 µl enhancer solution
was added and incubated at room temperature
for 5 min. 5 µl Effectene was added, the solu-
tion mixed with gentle vortexing, incubated at
room temperature for 10 min and a 1× volume
of 0.05% gelatin (Sigma) added. Samples were
printed with a Biorobotics MicroGrid II microar-
rayer onto polylysine slides (Sigma) in a 10 × 10
square, the pins hitting each spot twice. Each spot
was ∼140 µm in diameter. Arrays were stored des-
iccated at room temperature. Human embryonic
kidney (HEK293T) cells were grown and main-
tained in 500 ml DMEM with 0.11 g/l NA PYR
with pyroxidine containing 50 ml FCS, 100 U/ml
penicillin, 100 µg/ml streptomycin (Invitrogen) at
37 ◦C and 5% CO2. 10 × 106 cells were added to
20 ml culture medium and inverted four times to
mix. Three slides were placed in a 10 × 10 cm
square dish (Falcon) and the cell suspension poured
onto the slides. The dish was placed in a 37 ◦C,
5% CO2 incubator for 40 h, or until the cells were
completely confluent.
The slides were rinsed in PBS (Gibco) for 10 s,
fixed in 3.8% paraformaldehyde (38% paraformal-
dehyde (BDH), diluted to 3.8% with PBS) for
20 min, then dipped briefly in water to rinse. A
drop of mounting medium containing propidium
iodide stain (Vector) was applied to a coverslip
(Amersham) and lowered onto the slide. Fluores-
cence was visualized using a Nikon Eclipse E800
microscope with a BioRad confocal attachment.
Standard transfection
5 × 106 HEK293T cells in 2 ml culture medium
(as reverse transfection) were poured over circular
22 mm diameter cover slips (BDH) in six-well
plates 24 h before transfection. 0.4 µg destination
vector containing the GOI was added to 100 µl
buffer EC (Qiagen) and 3.2 µl enhancer, vortexed
and incubated at room temperature for 5–10 min.
10 µl Effectene was added, vortexed and incubated
at room temperature for 5–10 min and 600 µl
culture medium was added. Media was aspirated
from the six-well plate, 1.2 ml fresh media added
and the DNA transfection mix carefully pipetted
over the cells. The plates were placed in a 37 ◦C,
5% CO2 incubator for 40 h, or until the cells were
completely confluent. The cells on the cover slips
were fixed, stained and imaged as for the reverse
transfection.
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Database searches
The sequences of the 16 genes used in this study
were analysed using the subcellular localization
prediction programmes PsortII (http://psort.nibb.
ac.jp), ProtComp 4 (http://www.softberry.com)
and the signal peptide prediction programme Pre-
dictNLS (http://cubic.bioc.columbia.edu/predict
NLS).
Information on previous subcellular localization
studies and signal peptides was also obtained from
Swiss-Prot/TrEMBL (http://ca.expasy.org) via the
gene name.
Results
Sixteen genes were chosen from three different
functional classes; kinase, transcription factor and
surface receptor, with differing subcellular localiza-
tions to ensure that the findings were widely appli-
cable. The size and orientation of the gene inser-
tions were successfully validated via PCR (data not
shown). Protein expression was observed in all 16
of the C-terminal genes and 11 of the 16 N-terminal
genes printed on the array.
Ziauddin and Sabatini (2001) reported a trans-
fection efficiency of 30–80 cells/spot on their
arrays with a spot size of 120–150 µm. In the cur-
rent study, each gene was spotted in a 10 × 10
grid and the spots were approximately 140 µm
in size. Transfection efficiencies of up to 30
cells/spot were observed; however, this varied
greatly depending on the identity of the trans-
gene. All the C-terminal tagged proteins except one
had better transfection efficiencies than N-terminal
tagged proteins. Nine C-terminal-tagged proteins
(CXADR, TNFRSF10B, MARKL1, CDK9, TGIF,
IL17BR, CALM2, NFIB and CDKN1B) showed
transfection in 80% or more spots, with 10–30
cells transfected per spot. Five C-terminal tagged
proteins (SIP2-28, NFIL3, PTPN11, PPARG and
CDK7) showed transfection in 30–80% of spots,
with 5–10 cells transfected per spot. Finally, two
C-terminal tagged proteins, ATF4 and STK15,
showed transfections in only 5–30% of their spots,
with 2–5 cells transfected per spot. N-terminal
tagged proteins showed transfection in 2–40% of
their spots, with 2–10 cells transfected per spot.
The only protein to show better transfection effi-
ciency when tagged at the N-terminal was CDK7.
Of the 11 N-terminal tagged proteins expressed,
only six fusion proteins (ATF4, CALM2, CDK7,
CDK9, IL17BR and NFIB; Figure 2 and Table 2)
had the same subcellular localization as the C-
terminal fusions and are henceforth referred to
as group 1. Five of the N-terminal fusion pro-
teins (PTPN11, TNFRSF10B, TGIF, MARKL1 and
SIP2-28) had differing subcellular localizations to
the C-terminal fusion proteins (group 2; Figure 3).
Five of the N-terminal fusion proteins (CXADR,
NFIL3, PPARG and STK15 and CDKN1B) showed
no transfection events at all (group 3; Figure 3).
These results are summarized in Table 2.
All 32 transfections — 16 C-terminal and 16
N-terminal — were also undertaken using stan-
dard transfection techniques in six-well plates. The
results were identical; group 1 proteins showed the
same subcellular localizations whether tagged at
the N- or the C-terminal. Group 2 proteins had
the same localizations as recorded in the reverse
transfection, with differing subcellular localizations
depending on whether they were tagged at the C-
or N-terminal. Group 3 proteins showed the same
subcellular localizations at the C-terminal as the
reverse transfection and no localization signal at
the N-terminal (data not shown).
Swiss-Prot/TrEMBL (Boeckmann, 2003) record
subcellular localizations from the scientific lit-
erature and 12 of the 16 proteins here have
been studied previously. In seven cases the C-
terminal localizations in this study were identical to
the Swiss-Prot/TrEMBL entries; ATF4, CDKN1B,
NFIB, PPARG and STK15 were confirmed to
be nuclear, PTPN11 was confirmed to be cyto-
plasmic and CXADR was confirmed as plasma
membrane. Of the remaining five C-terminal sub-
cellular localizations, all were similar to Swiss-
Prot/TrEMBL. Our subcellular localizations for
CDK7, CDK9 and TGIF were the nucleus and
one other organelle, whereas Swiss-Prot/TrEMBL
reported the localization to be nucleus only. Previ-
ous studies could have been carried out in different
cell types which can make a difference to the local-
ization pattern. IL17BR and TNFRSF10B had been
recorded as localizing to the plasma membrane, we
found IL17BR in the endoplasmic reticulum and
TNFRSF10B in tubules and vesicles within the cell.
Two bioinformatic prediction programmes were
used to help support the localizations of pro-
teins in groups 1 and 3 and to determine which
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Figure 2. Group 1 C- and N-terminal tagged proteins with the same subcellular localization. A confocal microscope with
a ×60 oil lens was used to obtain 16 slices through the cell for each image. All images are of the whole cell except proteins
NFIB and IL17BR, which are slices to demonstrate the empty nucleus in IL17BR and the empty nucleoli in NFIB. Bar, 10 µm
subcellular localization was more likely to be cor-
rect for the group 2 proteins. Psort II and Prot-
Comp version 4 (Table 2) were chosen because
they integrated different prediction methods to
give a combined result. Psort II combines known
protein sorting signals and amino acid composi-
tions (Nakai, 1991, 1992, 1999) and then employs
the k -nearest-neighbour method, which uses the
results as a feature vector to calculate Euclidean
distances between proteins (Nakai, 2001). Each
organelle was given a subcellular localization like-
lihood score between 1% and 100%; results over
20% were recorded in this analysis.
ProtComp version 4 (Softberry) combines results
with proteins of known subcellular localization and
assumed subcellular localization (based on theoret-
ical evidence) and provides a score assigned by
neural networks. Each organelle was assigned a
subcellular localization likelihood score between
0 and 10; scores over 1 are recorded in Table 2.
These two programmes were chosen because they
predict a variety of organelle localizations, whereas
other prediction programmes provide a more lim-
ited readout. At least one of the two subcellu-
lar prediction programmes was in accordance with
the observed C-terminal subcellular localization for
each of the genes.
Four subcellular localizations, for NFIL3,
CALM2, MARKL1 and SIP2-28, were determined
that were not recorded by Swiss-Prot/TrEMBL.
NFIL3 was localized to the nucleus with the C-
terminal tag; the two bioinformatics programmes
also predicted the nucleus. MARKL1 was local-
ized to the mitochondria with the C-terminal
tag, which was predicted in both programmes.
CALM2 was localized to the nucleus/cytoplasm
with both the N- and C-terminal tags, which the
two programmes also predicted. SIP2-28 local-
ized to nuclear membrane and cytoplasm with the
C-terminal tag and nucleus and cytoplasm with
the N-terminal tag. SIP2-28 was predicted as most
likely to be nuclear with PsortII and equally likely
Copyright  2004 John Wiley & Sons, Ltd. Comp Funct Genom 2004; 5: 342–353.
Use of GFP fusion proteins for subcellular localization studies 349
T
ab
le
2.
T
he
pr
ot
ei
ns
w
er
e
cl
as
si
fie
d
in
to
th
re
e
gr
ou
ps
ac
co
rd
in
g
to
th
ei
r
su
bc
el
lu
la
r
lo
ca
liz
at
io
n
un
de
r
th
e
he
ad
in
g
‘G
ro
up
’
C
el
l
C
el
lL
o
ca
liz
at
io
n-
B
io
in
fo
rm
at
ic
L
o
ca
liz
at
io
n
P
re
di
ct
io
n
C
el
lL
o
ca
liz
at
io
n
C
el
lL
o
ca
liz
at
io
n
(T
hi
s
(P
re
vi
o
us
S
ig
na
l?
S
tu
dy
)
S
tu
di
es
)
P
ro
tc
o
m
p
V.
4
—
O
ve
r
1
G
en
e
M
G
C
L
en
gt
h
S
w
-P
ro
t/
P
S
O
R
T
II
—
P
re
di
ct
S
W
-
N
am
e
ID
G
ro
up
C
la
ss
(A
A
)
C
-T
E
R
M
N
-T
E
R
M
T
re
m
bl
O
V
E
R
20
%
L
D
B
P
L
D
B
N
N
A
L
L
N
ls
P
R
O
T
AT
F4
93
37
1
FA
C
TO
R
35
2
N
U
C
N
U
C
N
U
C
N
U
C
74
N
U
C
18
27
0
0
2.
3
6.
3
N
O
N
E
N
O
N
E
C
A
LM
2
52
26
1
KI
N
A
SE
15
0
N
U
C
/C
Y
TO
N
U
C
/C
Y
TO
N
O
N
E
C
Y
TO
52
C
Y
TO
23
15
0
2.
1
2.
6
N
O
N
E
N
O
N
E
N
U
C
22
N
U
C
0
0
2.
3
2.
3
C
D
K7
50
90
1
KI
N
A
SE
34
7
N
U
C
/C
Y
TO
N
U
C
/C
Y
TO
N
U
C
M
IT
O
39
N
U
C
18
14
0
17
26
5
1.
7
7.
7
N
O
N
E
N
O
N
E
ER
30
C
Y
TO
40
10
0
2.
1
3
C
D
K9
51
66
1
KI
N
A
SE
37
3
N
U
C
/C
Y
TO
N
U
C
/C
Y
TO
N
U
C
C
Y
TO
65
N
U
C
19
51
0
60
30
2.
1
7.
1
N
O
N
E
N
O
N
E
N
U
C
26
C
Y
TO
0
0
2.
2
2.
2
IL
17
BR
52
45
1
RE
C
EP
TO
R
50
3
ER
ER
PM
ER
44
PM
0
0
2.
2
2.
2
N
O
N
E
N
-T
ER
M
G
O
LG
I
33
EC
0
0
2.
1
2.
1
PM
22
N
FI
B
51
46
1
FA
C
TO
R
42
1
N
U
C
N
U
C
N
U
C
N
U
C
78
N
U
C
22
49
5
0
2.
3
7.
3
N
O
N
E
N
O
N
E
PT
PN
11
17
20
6
2
RE
C
EP
TO
R
46
1
C
Y
TO
N
U
C
/C
Y
TO
C
Y
TO
C
Y
TO
35
C
Y
TO
24
59
0
24
36
0
1.
6
9.
8
N
O
N
E
N
O
N
E
M
IT
O
26
M
IT
O
0
0
1.
8
1.
8
TN
FR
-S
F1
0B
51
44
2
FA
C
TO
R
44
1
TU
B/
V
ES
N
U
C
PM
ER
26
EC
0
0
1.
9
1.
9
N
O
N
E
N
-T
ER
M
PM
26
M
IT
O
0
0
1.
2
1.
2
TG
IF
50
66
2
FA
C
TO
R
27
3
N
U
C
/P
U
N
C
T
C
Y
TO
N
U
C
/C
Y
TO
N
U
C
N
U
C
48
N
U
C
14
13
0
0
2.
3
5.
4
N
O
N
E
N
O
N
E
EC
22
M
A
RK
L1
17
73
9
2
KI
N
A
SE
80
M
IT
O
N
U
C
N
O
N
E
M
IT
O
39
PM
15
60
12
20
0.
9
1.
4
N
O
N
E
N
O
N
E
C
Y
TO
39
M
IT
O
0
0
1.
3
1.
3
EC
0
0
1.
3
1.
3
N
U
C
14
30
0
0.
7
1
SI
P2
-2
8
51
48
2
KI
N
A
SE
19
2
N
U
C
M
EM
/C
Y
TO
N
U
C
/C
Y
TO
N
O
N
E
N
U
C
70
C
Y
TO
0
24
30
2.
3
2.
6
N
O
N
E
N
O
N
E
M
IT
O
30
N
U
C
0
0
2.
2
2.
2
M
IT
O
0
0
1.
2
1.
2
EC
0
20
40
0.
9
1.
1
C
X
A
D
R
50
86
3
RE
C
EP
TO
R
36
6
M
V
/S
S
N
O
N
E
PM
EC
35
PM
18
95
0
0
2.
3
6.
6
N
O
N
E
N
-T
ER
M
PM
30
EC
0
0
2.
3
2.
3
(P
O
TE
N
TI
A
L)
ER
22
PE
RO
X
0
0
1.
1
1.
1
N
FI
L3
50
38
3
FA
C
TO
R
46
3
N
U
C
N
O
N
E
N
O
N
E
N
U
C
87
N
U
C
0
0
2.
3
2.
3
N
-T
ER
M
N
O
N
E
PP
A
RG
50
41
3
RE
C
EP
TO
R
47
8
N
U
C
N
O
N
E
N
U
C
C
Y
TO
65
N
U
C
24
70
0
71
80
2.
4
8.
6
N
-T
ER
M
N
O
N
E
N
U
C
22
C
Y
TO
0
0
1.
7
1.
7
ST
K1
5
51
33
3
KI
N
A
SE
40
4
N
U
C
N
O
N
E
C
EN
T/
SP
(N
U
C
)
N
U
C
78
N
U
C
43
50
0
2.
2
3.
2
N
O
N
E
N
O
N
E
C
Y
TO
42
20
43
75
0.
8
2.
3
ER
0
0
1.
2
1.
2
C
D
KN
1B
53
04
3
KI
N
A
SE
19
9
N
U
C
N
O
N
E
N
U
C
N
U
C
78
N
U
C
10
56
5
98
30
2.
3
5.
7
N
O
N
E
C
-T
ER
M
(P
O
TE
N
TI
A
L)
G
ro
up
1,
sa
m
e
su
bc
el
lu
la
r
lo
ca
liz
at
io
ns
w
ith
N
-
an
d
C
-t
er
m
in
al
ta
gg
ed
G
FP
fu
sio
n
pr
ot
ei
ns
;g
ro
up
2,
di
ffe
rin
g
su
bc
el
lu
la
r
lo
ca
liz
at
io
ns
w
ith
N
-
an
d
C
-t
er
m
in
al
ta
gg
ed
G
FP
pr
ot
ei
ns
;g
ro
up
3,
su
bc
el
lu
la
r
lo
ca
liz
at
io
ns
ob
se
rv
ed
w
ith
C
-t
er
m
in
al
-t
ag
ge
d,
bu
t
no
t
w
ith
N
-t
er
m
in
al
-t
ag
ge
d,
G
FP
pr
ot
ei
ns
.O
ur
su
bc
el
lu
la
r
lo
ca
liz
at
io
ns
,p
re
vi
ou
s
Sw
iss
-P
ro
t/
Tr
EM
BL
lo
ca
liz
at
io
ns
an
d
Ps
or
t
II
an
d
Pr
ot
C
om
p
4
lo
ca
liz
at
io
n
pr
ed
ic
tio
ns
w
er
e
re
co
rd
ed
.S
ig
na
lp
ep
tid
e
lo
ca
tio
ns
w
er
e
re
co
rd
ed
us
in
g
Pr
ed
ic
tN
LS
an
d
Sw
iss
-P
ro
t/
Tr
EM
BL
.L
ig
ht
gr
ey
bo
xe
s
in
di
ca
te
eq
ui
va
le
nt
su
bc
el
lu
la
r
co
m
pa
rt
m
en
ts
be
tw
ee
n
th
e
su
bc
el
lu
la
r
lo
ca
liz
at
io
ns
fr
om
th
is
st
ud
y
an
d
pr
ev
io
us
an
d
pr
ed
ic
te
d
su
bc
el
lu
la
r
lo
ca
liz
at
io
ns
.D
ar
k
gr
ey
bo
xe
s
in
di
ca
te
sig
na
ls
eq
ue
nc
es
.A
A
,a
m
in
o
ac
id
s;
C
EN
T,
ce
nt
ro
so
m
e;
C
Y
TO
,c
yt
op
la
sm
;E
C
,e
xt
ra
ce
llu
la
r;
ER
,e
nd
op
la
sm
ic
re
tic
ul
um
;L
Y
SO
,l
ys
os
om
e;
M
IT
O
,m
ito
ch
on
dr
ia
;M
V
,m
ic
ro
vi
lli;
N
U
C
,n
uc
le
us
;N
U
C
M
EM
,n
uc
le
ar
m
em
br
an
e;
PE
RO
X
,p
er
ox
iso
m
e;
PM
,p
la
sm
a
m
em
br
an
e;
PU
N
C
T
C
Y
TO
,p
un
ct
at
e
cy
to
pl
as
m
;S
P,
sp
in
dl
e
po
le
;S
S,
su
rfa
ce
st
ru
ct
ur
es
;T
U
B,
tu
bu
le
;V
ES
,v
es
ic
le
s;
N
LS
,n
uc
le
ar
lo
ca
liz
at
io
n
sig
na
l;
C
-T
ER
M
,C
-t
er
m
in
al
-t
ag
ge
d
G
FP
;N
-T
ER
M
,N
-t
er
m
in
al
-t
ag
ge
d
G
FP
;S
W
-P
RO
T,
Sw
iss
-P
ro
t/
Tr
EM
BL
;L
D
B,
lo
ca
liz
at
io
n
fro
m
da
ta
ba
se
;P
LD
B,
pr
ed
ic
te
d
lo
ca
tio
n
fr
om
da
ta
ba
se
;N
N
,
ne
ur
al
ne
tw
or
ks
;A
LL
,c
om
bi
ne
d
re
su
lts
fr
om
LD
B,
PL
D
B
an
d
N
N
.
Copyright  2004 John Wiley & Sons, Ltd. Comp Funct Genom 2004; 5: 342–353.
350 E. Palmer and T. Freeman
Figure 3. Group 2, C and N-terminal tagged proteins with differing subcellular localizations. Group 3, C-terminal tagged
protein subcellular localizations (N-terminal tagged proteins did not localize). A confocal microscope with a ×60 oil lens
was used to obtain 16 slices through the cell for each image. All images are of the whole cell except TGIF, NFIL3 and
PPARG, which are slices to demonstrate the empty nucleoli, and SIP2-28, which is a slice to demonstrate the empty
nucleus. Bar, 10 µm
to be nucleus or cytoplasm with ProtComp version
4; it is therefore difficult to determine which is the
correct localization for SIP2-28, as the results are
so similar.
Five genes (PTPN11, TNFRSF10B, TGIF,
MARKL1 and SIP2-28: group 2; Figure 2 and
Table 2) differed in localization when tagged with
GFP at the N- or C-terminal end. C-terminal-tagged
PTPN11 localized to the cytoplasm and N-terminal
to the nucleus/cytoplasm in this study. The Swiss-
Prot/TrEMBL localization was cytoplasmic and
both bioinformatics studies predicted the cytoplasm.
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C-terminal-tagged TNFRSF10B localized to
tubules/vesicles and N-terminal to the nucleus, the
Swiss-Prot/TrEMBL localization was the plasma
membrane, Psort II predicted the endoplasmic retic-
ulum and plasma membrane as equally likely local-
izations and the ProtComp version 4 prediction
was extracellular. C-terminal-tagged TGIF local-
ized to the nucleus, with small punctate bod-
ies within the cytoplasm and N-terminal to the
nucleus/cytoplasm. The Swiss-Prot/TrEMBL local-
ization is nuclear and both programmes predicted
the nucleus. C-terminal tagged MARKL1 localized
to mitochondria and N-terminal to the nucleus, the
mitochondria was predicted as a highly likely local-
ization by both programmes. In each case the C-
terminal localization was more likely to be correct.
SIP2-28 was observed as in the previous paragraph.
N-terminal tagged group 3 proteins showed no
expression at all and N-terminal tagged group 2
proteins show a different localization when tagged
at the C-terminal (Figure 3, Table 2). The C-
terminal localizations were concluded to be more
likely to be correct in each case, after compari-
son (above) with previous subcellular localization
studies and results from bioinformatic predictions.
The GFP tagging of the GOI at the N-terminal end
would therefore appear to be having a detrimen-
tal effect on protein localization. A possible cause
could be the location of the signal sequence, which
is more often at the N-terminal end of the protein.
In order to examine the proteins for the presence
of a protein-sorting sequence, Swiss-Prot (Boeck-
mann, 2003) and the PredictNLS programme
(Cokol, 2000) were used. Swiss-Prot records any
known targeting sequences from the literature; if
none are found, the sequence is analysed using
the programme Signal P (Neilsen, 1997). Signal
P is based on neural networks trained on sepa-
rate sets of eukaryote and prokaryote sequences,
if a signal peptide is predicted it is recorded in
Swiss-Prot as ‘potential’. PredictNLS checks the
protein sequence for a match to 214 potential
nuclear localization signals (NLS). The programme
only predicts signal peptides for localization to the
nucleus, but was chosen since we found eight of the
16 proteins in this study to localize to the nucleus
with the N- or C-terminal tag. Six predicted tar-
geting sequences were found in the 16 proteins
(Table 2). An N-terminal signal sequence was dis-
covered in three group 3 proteins (CXADR, NFIL3
and PPARG), one group 2 protein (TNFRSF10B)
and one group 1 protein (IL17BR). A single C-
terminal signal sequence was predicted in the group
3 protein CDKN1B.
Discussion
Reverse transfection arrays have the potential to
provide a high throughput means of screening for
gene function. Our aim was to explore their util-
ity as a method for determining the subcellular
localization of proteins. In this pilot study, 16
genes from a variety of functional classes that had
different subcellular localizations were chosen, in
order to ensure that the findings would be appli-
cable to a variety of different gene classes. Their
ORFs were amplified from full-length MGC cDNA
clones and inserted into N- and C-terminal GFP
Gateway expression vectors. The expression con-
structs were then packaged in transfection reagent
and printed onto a glass slide to form a microarray.
HEK293T cells were grown on top of the slide until
confluent and patches of transfected cells overex-
pressing the genes were formed. GFP was chosen to
tag the ORFs, as it can be visualized easily via con-
focal microscopy, with no further need for manip-
ulation of the arrays. Due to the relatively large
size of GFP, N- and C-terminal fusions were con-
structed to explore the optimal position of the tag
with respect to normal localizations of the protein.
In some cases transfection efficiencies were com-
parable with those reported by Sabatini and Ziaud-
din, with 30–80 of cells transfected per spot. How-
ever, they varied greatly in this study, from as
little as 5% to more than 80% of spots trans-
fected per protein, with 2–30 cells transfected
per spot. The variation in transfection efficiency
could be due to the number of gene copies
within the cell, the rate of gene transcription and
the stability of the mRNA transcript (Colosimo,
2000). In categorizing and determining whether
the observed subcellular localizations were cor-
rect, Swiss-Prot/TrEMBL, Psort II and Protcomp
4 were very useful. Swiss-Prot/TrEMBL records
any previous subcellular localizations of proteins
reported in the literature, Psort II and Protcomp
4 predict localizations. Subcellular localizations
for 12 of the 16 proteins studied here were
recorded in Swiss-Prot/TrEMBL and novel subcel-
lular localizations were observed for the remaining
four (NFIL3, CALM2, MARKL1 and SIP2-28).
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NFIL3 is a transcription factor, which explains its
occurrence in the nucleus in this study. CALM2,
together with the proteins CALM1 and CALM3
form the protein calmodulin (Tootenhoofd, 1998);
we found CALM2 equally distributed throughout
the nucleus and cytoplasm. MARKL1 was found
in the mitochondria, there is little other infor-
mation available on this gene. SIP2-28 is a cal-
cium binding protein, which binds to the cyto-
plasmic domains of integrin αIIb; in this study
it localized to the nucleus/nuclear membrane and
the cytoplasm. These subcellular localizations were
all supported by the bioinformatics prediction pro-
grammes (Table 2). This study, however, is too
small to draw any conclusions about the general
accuracy of protein localization prediction pro-
grammes.
All 16 of the C-terminal tagged proteins local-
ized correctly, but this was the case for less
than half of the N-terminal tagged proteins. N-
terminal signal peptides were found in the group 2
and 3 proteins TNFRSF10B, CXADR, NFIL3 and
PPARG (these groups contained N-terminal-tagged
proteins that either did not localize correctly or did
not show any protein expression). This supports
evidence that N-terminal GFP tagging of a protein
can cause the signal sequence at the N-terminus
to be masked. The lack of expression or mislo-
calization of the N-terminal tagged proteins could
possibly be explained further. Proteins emerge from
the ribosome into the cytoplasm N-terminus first
and chaperones prevent the amino acid chain from
folding until a whole domain, 50–300 amino acids
long, has emerged (Hartl, 2002). GFP is 238 amino
acids long and will fold first if tagged at the N-
terminal end, possibly disrupting further folding
and correct localization of the protein, regardless
of whether its signal sequence is at the N- or C-
terminal end. In some cases the protein may disrupt
the folding of the GFP itself, giving rise to the
observation of group 3 proteins, i.e. no visible pro-
tein expression. C-terminal tagging of the protein
with GFP would not have the same effect, as the
GFP will be folded last and will not influence the
native or GFP protein conformation. Overall, this
study suggests that C-terminal tagging of a pro-
tein with GFP is generally superior to N-terminal
tagging, as the protein is more likely to localize
correctly and therefore it is to be expected that it
will maintain the functional characteristics of the
native protein.
A number of groups have recently reported
results from large-scale subcellular localization
studies using 96-well plates (Wiemann, 2003; Huh,
2003). Weimann et al. performed subcellular local-
ization studies on over 500 C- and N-terminal flu-
orescently tagged human genes from the German
cDNA consortium collection (Weimann, 2001).
Huh et al. localized 6029 C-terminal GFP tagged
ORFs from Saccharomyces cerevisiae. Weimann
et al. concluded that most signal peptides located
at the N-terminus of proteins, such as those that
direct proteins to the mitochondria and plasma
membrane, were masked by the N-terminal GFP
fusion, as our study also demonstrates (see group 2
proteins; Figure 3). Huh et al. tagged their ORFs at
the C-terminus only; 80% of their subcellular local-
izations were in agreement with previous findings,
but they concluded that proteins localized to the
cell wall, peroxisome and ER, which often contain
C-terminal targeting signals, were mislocalized due
to the C-terminal GFP. Therefore, both these large-
scale studies and the pilot study described here are
in agreement — the majority of C-terminal tagged
ORFs localize correctly, as most signal peptides
are at the N-terminus, but it is preferable to tag at
both ends, as some signal peptides are found at the
C-terminus.
In theory, reverse transfection has an advantage
over plate-based assays, in that more plasmids can
be transfected simultaneously. However, this study
has exposed some of the inherent challenges in
setting up this technology as a high-throughput sys-
tem. Whilst large collections of sequence-verified
full-length cDNA clones are available via the MGC
(Strausberg, 2002), the Full Length Expression
(FLEX) repository initiative (Brizuela, 2002) and
the German cDNA consortium (Weimann, 2001),
these genes are not tagged. Sub-cloning of the
ORFs into the Gateway cloning system is relatively
expensive, time-consuming and could potentially
introduce errors into the ORFs; therefore, ideally,
the clones need to be resequenced. Another issue
is imaging these arrays. A high-throughput imaging
system would undoubtedly be needed to systemati-
cally record the subcellular localizations of proteins
and/or read-outs of downstream assays if any num-
ber of genes/arrays were to be processed at any
time. The necessity for spot recognition software
and the storage and analysis of the images present
a considerable challenge. These issues are currently
being explored and a microscope-based screening
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platform is being developed with automated sam-
ple preparation, image acquisition and data analysis
(Wiemann, 2003; Liebel, 2003). If these challenges
can be overcome, reverse transfection technology
could prove to be an enormously powerful tool for
the characterization of gene function.
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